Saturday, July 17, 2021 2:04:59 PM
For the current standards of care:
Almost all patients experience tumor progression with nearly universal mortality and a median survival of less than 15 months from surgery, with a 2-year survival rate of 26–33%. To date, no new agents improve survival when added to standard therapy.
[source: https://www.ncbi.nlm.nih.gov/books/NBK469987/]
For the current DCVax-L P3 trial for GBM:
Population n Median OS since surgery Survival at 1 year Survival at 2 years Survival at 3 years
2017 data 331 23.1 months 89.3% 46.2% 25.4%
2018 data 331 23.1 months 89.3% 46.4% 28.2
[see as time goes by, the trend is that the OS has improved]
more detailed breakdown:
Data set n Median OS since surgery Survival at 1 year Survival at 2 years Survival at 3 years
2017 methylated 131 34.7 months 94.5% 66.7% 46.4%
2018 methylated 131 35.1 months 94.6% 66.6% 49.1%
2017 unmethylated 162 19.8 months 86.4% 32.1% 11.0%
2018 unmethylated 162 19.8 months 86.4% 32.6% 14.3
[source: https://nwbio.com/update-on-dc-vax-at-asco-2019/]
[Based on what we have know today as fact shown above, the odds of DCVax-L gained approved by FDA is substantially high (> 80%)]
Then, there is the current evolution version of FDA: Demonstrating Substantial Evidence of Effectiveness for Human Drug and
Biological Products Guidance for Industry -- https://www.fda.gov/media/133660/download]
and there is WHO's updated GBM definition which is highly in favor of DCVax-L's approval.
Finally, the principle for FDA to approve a new agent has always been the assessment of benefit-risk of the underlying agent. For DCVax-L, we know as fact it's safe almost without any side effects, so as long as nwbo can show concrete evidence that the vaccine is efficacious in treatment GBM, no regulatory agencies can deny its approval [a bit of rhetoric].
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM